HC Wainwright Lowers Valneva (NASDAQ:VALN) Price Target to $17.00

Valneva (NASDAQ:VALN) had its price objective cut by analysts at HC Wainwright from $18.00 to $17.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 114.92% from the stock’s current price.

Valneva Stock Up 4.9 %

NASDAQ:VALN opened at $7.91 on Wednesday. The firm’s 50-day moving average price is $5.18 and its 200-day moving average price is $5.67. The company has a market capitalization of $642.77 million, a PE ratio of -60.85 and a beta of 1.98. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. Valneva has a 1-year low of $3.62 and a 1-year high of $9.50.

Institutional Trading of Valneva

Institutional investors have recently bought and sold shares of the company. ABC Arbitrage SA purchased a new stake in Valneva during the 4th quarter valued at about $84,000. AlphaCentric Advisors LLC grew its position in Valneva by 33.7% during the 3rd quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company’s stock valued at $717,000 after purchasing an additional 29,748 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after purchasing an additional 30,859 shares during the last quarter. 11.39% of the stock is owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.